ABCL
AbCellera Biologics Inc.
$7.87
-0.24 (-2.96%)
At close · Jul 6
Market Cap
$2.40B
Shares
305,375,393
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.87
Open$8.05
Day$7.45–8.15
52W$2.75–8.42
Avg vol 30d7.8M
Short int44.9M · 14.7% float · 7.1d
Short vol57%
Last earningsMay 11, 2026
DataDec 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+79% above
+
Price vs 50-day avg
+45% above
◦
RSI (14)
69 · neutral
+
MACD trend
positive
+
52-week position
90% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $5 › 200d $4 — 50d above 200d
−
Institutional flow
-5% holders QoQ · +20 funds added
+
Insider flow
Net +$95.4K over 90 days · 0% sells
+
Short interest
14.71% of float · ▼ -4.7% MoM · 7.1 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
139 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+161% Y/Y
+
EPS growth
+11% Y/Y
−
Free cash flow
$-174.1M
+
Balance sheet
net cash $128.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+79% above
Bullish
Price vs 50-day avg
+45% above
Bullish
RSI (14)
69 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
90% · near high
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Distributing
-5% holders QoQ · +20 funds added
Insider flow
Accumulating
Net +$95.4K over 90 days · 0% sells
Short interest
Falling
14.71% of float · ▼ -4.7% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
139 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $8 · 90%
52-wk high $8
vs 200-day avg +79%
vs 50-day avg +45%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Molecules in the clinic with downstreams | 14 | Q1 2026 | — |
| Total available liquidity | $655M | Q1 2026 | — |
| Available liquidity | $700M | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABCL
this stock
AbCellera Biologics Inc.
|
$2.40B | +130.1% | -92.2% | — | 14.7% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABCL | +6.6% | +23.6% | +80.1% | +0.3% | +130.1% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +3.6% | +24.3% | +71.9% | -0.4% | +120.0% |